Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

Rhea-AI Summary

Lilly (NYSE: LLY) will highlight its expanding hematology portfolio at the 2026 European Hematology Association (EHA) Annual Meeting in Stockholm, June 11-14.

Key presentations cover Phase 3 BRUIN CLL-322 data for Jaypirca in relapsed/refractory CLL/SLL, plus early-stage programs from Ajax Therapeutics and Kelonia Therapeutics, which Lilly has agreed to acquire.

News Market Reaction – LLY

-1.67%

-1.67% Session close to close

In the Jun 2 session, LLY declined 1.67%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Lilly’s expanding hematology strategy, centered on positive Phase 3 BRU...

Analysis

This announcement highlights Lilly’s expanding hematology strategy, centered on positive Phase 3 BRUIN CLL-322 results for pirtobrutinib and early-stage programs from Ajax and Kelonia in myelofibrosis and multiple myeloma. Together with prior oncology and cardiometabolic updates, it underscores a diversified pipeline across modalities. Investors may track detailed EHA data, timelines for closing Ajax and Kelonia in 2026, and how new clinical results integrate with Lilly’s broader oncology portfolio.

Key Figures

Phase 3 study: Phase 3 BRUIN CLL-322 Phase 1 AJX-101: Phase 1 Phase 1 inMMyCAR: Phase 1 +5 more

8 metrics

Phase 3 study Phase 3 BRUIN CLL-322 Pirtobrutinib plus venetoclax–rituximab vs venetoclax–rituximab in CLL/SLL

Phase 1 AJX-101 Phase 1 AJ1-11095 in myelofibrosis after failure of type I JAK2 inhibitor

Phase 1 inMMyCAR Phase 1 KLN-1010 in relapsed/refractory multiple myeloma

EHA meeting dates June 11–14, 2026 European Hematology Association Annual Meeting in Stockholm

Late-breaking session time June 14, 9:15–10:45 BRUIN CLL-322 late-breaking oral session

Poster session window June 13, 18:45–19:45 Pirtobrutinib pooled results in treatment-naïve CLL/SLL

Oral session slot June 13, 18:00–18:15 AJ1-11095 Phase 1 myelofibrosis data

Oral session slot June 11, 16:45–17:00 KLN-1010 in vivo CAR-T multiple myeloma data

Historical Context

5 past events · Latest: May 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 28	Obesity coverage expansion	Positive	+4.0%	Expanded PBM coverage for Foundayo and Zepbound improving patient access.
May 27	Conference participation	Neutral	+1.7%	Announcement of participation in Goldman Sachs healthcare conference webcast.
May 26	Infectious disease deals	Neutral	-0.0%	Agreements to acquire three vaccine-focused companies to expand portfolio.
May 25	PCSK9 base editor data	Positive	-0.0%	Strong Phase 1b VERVE-102 LDL-C and PCSK9 reductions with favorable safety.
May 21	ASCO oncology showcase	Positive	+2.2%	Broad ASCO presence with multiple Phase 3 and early oncology programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been followed by modest positive moves, with occasional divergence even on strong clinical updates.

Recent Company History

Over the past few weeks, LLY has issued several upbeat updates. Obesity portfolio access expansions on May 28 and a major ASCO oncology showcase on May 21 were followed by gains of 4.05% and 2.24%, respectively. A transformative infectious disease acquisition set on May 26 and strong base-editing data on May 25 saw essentially flat reactions around -0.02%. Today’s hematology-focused EHA announcement continues the theme of broad pipeline and modality build-out, including blood cancers, alongside prior cardiometabolic and oncology advances.

Key Terms

phase 3, bruton tyrosine kinase (btk) inhibitor, progression-free survival (pfs), jak2 inhibitor, +4 more

8 terms

phase 3 medical

"Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

bruton tyrosine kinase (btk) inhibitor medical

"Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor..."

A Bruton tyrosine kinase (BTK) inhibitor is a drug that blocks a specific enzyme (BTK) used by certain immune and blood cells to send growth and activation signals, like turning off a faulty switch that keeps those cells overactive. Investors care because BTK inhibitors are developed to treat blood cancers and autoimmune diseases, and clinical trial results, safety and regulatory approval determine a drug’s commercial value and the issuing company’s future revenue prospects.

progression-free survival (pfs) medical

"led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS)."

Progression-free survival (PFS) measures the length of time in a clinical trial or treatment period during which a patient’s disease does not get worse. Investors watch PFS because longer PFS in trials can signal a drug’s effectiveness, influence regulatory approval and reimbursement decisions, and affect commercial value—think of it as how long a product keeps a problem from returning, which helps estimate future sales and competitive advantage.

jak2 inhibitor medical

"first-in-class type II JAK2 inhibitor for patients with myelofibrosis..."

A JAK2 inhibitor is a type of medicine that blocks the JAK2 protein, which acts like a control knob that tells certain blood and immune cells to grow and act. For investors, these drugs matter because successful JAK2 inhibitors can treat serious blood or immune disorders, potentially creating substantial revenue if approved, while clinical trial results, safety issues, or regulatory decisions can quickly change a company’s valuation—similar to how a single product can make or break a small manufacturer.

myelofibrosis medical

"in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor."

A bone marrow disorder in which healthy, spongy marrow is gradually replaced by scar tissue, like a garden soil turned to concrete so seeds can’t grow. That replacement reduces production of red and white blood cells and platelets, causing anemia, fatigue, infections and an enlarged spleen. Investors care because the condition creates demand for therapies, clinical trials and regulatory decisions that can materially affect drug sales and company valuations.

car-t medical

"its in vivo CAR-T program in patients with multiple myeloma..."

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

minimal residual disease (mrd) medical

"Successful in vivo CAR-T generation and minimal residual disease (MRD) clearance..."

The presence of minimal residual disease (MRD) means a very small number of cancer cells remain in the body after treatment, too few to cause symptoms or show up on routine scans but detectable with sensitive tests. For investors it matters because MRD status is a strong early indicator of whether a patient is likely to relapse and is increasingly used as a trial endpoint and regulatory signal, affecting a therapy’s market prospects and valuation much like finding glowing embers after a fire signals risk of re-ignition.

multiple myeloma medical

"in patients with relapsed and refractory multiple myeloma."

A cancer of the blood that starts in plasma cells, the immune system’s antibody-producing cells in bone marrow. It behaves like a factory where the workers go rogue, crowding out healthy cells and causing bone damage, anemia and infections; treatments and trial results can sharply affect drug sales, regulatory approvals and company valuations, so progress or setbacks are closely watched by investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL will be highlighted in a late-breaking oral presentation

Ajax Therapeutics, which Lilly has agreed to acquire, will present the first clinical data for its first-in-class type II JAK2 inhibitor for patients with myelofibrosis who have been failed by a type I JAK2 inhibitor

Kelonia Therapeutics, which Lilly has agreed to acquire, will present additional correlative clinical data for its in vivo CAR-T program in patients with multiple myeloma 

INDIANAPOLIS, June 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) Annual Meeting, taking place June 11-14 in Stockholm, Sweden.

Data to be highlighted include an oral presentation detailing results from the Phase 3 BRUIN CLL-322 study of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, as part of a time-limited regimen for patients with previously treated chronic lymphocytic leukemia (CLL). Lilly is strengthening its hematology portfolio through the recently announced proposed acquisitions of Ajax Therapeutics, Inc.^* and Kelonia Therapeutics, Inc.^*, each of which will present data at the meeting. Ajax Therapeutics will present the first clinical data from the Phase 1 AJX-101 study evaluating AJ1-11095, an investigational first-in-class type II JAK2 inhibitor, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. Kelonia Therapeutics will present additional correlative data from the Phase 1 inMMyCAR study of an investigational anti-B-cell maturation antigen (BCMA) targeted in vivo CAR-T therapy in patients with relapsed and refractory multiple myeloma. Both proposed acquisitions by Lilly are pending transaction closes.

"These data at EHA represent a significant moment for Lilly's hematology ambitions," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "The Phase 3 BRUIN CLL-322 results address an important question for patients with relapsed or refractory CLL, demonstrating that time-limited pirtobrutinib can meaningfully improve outcomes when added to an already effective venetoclax-based regimen. Alongside the first clinical data from Ajax and additional results from Kelonia in support of the recently presented data at ASCO, these results reflect our relentless commitment to pursue meaningful advancements for people living with blood disorders."

Presentation Highlights:

Lilly:

• In a late-breaking oral presentation, Lilly will share results from the Phase 3 BRUIN CLL-322 study, evaluating a time-limited regimen of pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL. BRUIN CLL-322 is the first Phase 3 readout in CLL to outperform a venetoclax-containing control arm in any CLL setting. Lilly previously announced that the study met its primary endpoint, demonstrating that the addition of pirtobrutinib to venetoclax plus rituximab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS). These results were also selected to be featured in the EHA press program.

Ajax Therapeutics:

• In an oral presentation, Ajax will share the first clinical results from the Phase 1 AJX-101 clinical trial, evaluating AJ1-11095, an investigational first-in-class type II JAK2 inhibitor, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor. These data will also be featured in the EHA press program.  

Kelonia Therapeutics:

• In an oral presentation, Kelonia will share additional correlative data from the Phase 1 inMMyCAR dose-escalation study, evaluating KLN-1010 in relapsed or refractory multiple myeloma. Data from this study were recently shared at the American Society of Clinical Oncology (ASCO) Annual Meeting.  

A full list of abstract titles and viewing details are listed below:

Abstract Title	Author	Presentation Type/#		Session Title	Session Date/Time (CEST)
Jaypirca (pirtobrutinib; non-covalent BTK inhibitor)
Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated CLL/SLL: A phase 3, randomized study (BRUIN CLL-322)	Matthew Davids	Oral #LB5001		Late-breaking oral session	Sunday, June 14 9:15 – 10:45
Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314	Jennifer Woyach	Poster #PS1701		Chronic lymphocytic leukemia and related disorders - Clinical	Saturday, June 13 18:45 – 19:45
Patient-reported outcomes of pirtobrutinib vs. bendaR in untreated CLL/SLL: Findings from BRUIN-CLL-313 Phase 3 study	Tomasz Wrobel	Poster #PF1386		Quality of life, ethics, supportive and palliative care	Friday, June 12 18:45 - 19:45
Investigator Initiated A Phase 2 study of fixed-duration pirtobrutinib and obinutuzumab in previously untreated CLL	Inhye E. Ann	Oral Session #S148		Prognostication and first line therapy in CLL	Friday, June 12 18:00 – 18:15
AJ1-11095 (Ajax's investigational first-in-class type II JAK2 inhibitor)
Results of AJX-101, a Phase 1 clinical trial of the type II JAK2 inhibitor AJ1-11095, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor	John Mascarehas	Oral Session #S218	Myeloproliferative neoplasms - Clinical		Saturday, June 13 18:00 – 18:15
KLN-1010 (Kelonia's investigational in vivo CAR-T therapy)
Successful in vivo CAR-T generation and minimal residual disease (MRD) clearance with KLN-1010 across diverse baseline T Cell phenotypes in relapsed/refractory multiple myeloma (RRMM)	Andrew Spencer	Oral Session #S185	T cell redirected therapy in multiple myeloma		Thursday, June 11 16:45 – 17:00

For more information on Lilly's oncology pipeline click here.

*Lilly and Ajax Therapeutics, Inc., and Lilly and Kelonia Therapeutics, Inc., remain separate, independent companies prior to closing. Both transactions are subject to customary closing conditions, including regulatory approvals, with Ajax Therapeutics expected to close in June 2026 and Kelonia Therapeutics expected to close in the second half of 2026.

About Jaypirca (pirtobrutinib) 
Jaypirca (pirtobrutinib) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent inhibitor of the enzyme BTK.¹ BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).^2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.

INDICATIONS FOR JAYPIRCA (pirtobrutinib)
Jaypirca is indicated for the treatment of

• Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
• Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 

IMPORTANT SAFETY INFORMATION FOR JAYPIRCA (pirtobrutinib)

Infections: Fatal and serious infections (including bacterial, viral, fungal) and opportunistic infections occurred in Jaypirca-treated patients. Across clinical trials, Grade ≥3 infections occurred (25%), most commonly pneumonia (20%); fatal infections (5%), sepsis (6%), and febrile neutropenia (3.8%) occurred. In patients with CLL/SLL, Grade ≥3 infections occurred (32%), with fatal infections occurring in 8%. Opportunistic infections included Pneumocystis jirovecii pneumonia and fungal infection. Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients at increased risk for infection, including opportunistic infections. Monitor for signs and symptoms, evaluate, and treat. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Hemorrhage: Fatal and serious hemorrhage has occurred with Jaypirca. Across clinical trials, major hemorrhage (Grade ≥3 bleeding or any central nervous system bleeding) occurred (2.6%), including gastrointestinal hemorrhage; fatal hemorrhage occurred (0.3%). Bleeding of any grade, excluding bruising and petechiae, occurred (16%). Major hemorrhage occurred when taking Jaypirca with (2.0%) and without (0.6%) antithrombotic agents. Consider risks/benefits of co-administering antithrombotic agents with Jaypirca. Monitor for signs of bleeding. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca. Consider withholding Jaypirca 3-7 days pre- and post-surgery based on surgery type and bleeding risk.

Cytopenias: Jaypirca can cause cytopenias, including neutropenia, thrombocytopenia, and anemia. Across clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (27%), decreased platelets (13%), and decreased hemoglobin (11%), developed. Grade 4 decreased neutrophils (15%) and Grade 4 decreased platelets (6%) developed. Monitor complete blood counts regularly. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Cardiac Arrhythmias: Cardiac arrhythmias occurred in patients taking Jaypirca. Across clinical trials, atrial fibrillation or flutter were reported in 3.4% of Jaypirca treated patients, with Grade 3 or 4 atrial fibrillation or flutter in 1.6%. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred (0.4%). Cardiac risk factors such as hypertension or previous arrhythmias may increase risk. Monitor and manage signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea). Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Second Primary Malignancies: Across clinical trials, second primary malignancies, including non-skin carcinomas, developed in 9% of Jaypirca-treated patients, most frequently non-melanoma skin cancer (4.4%). Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor for development of second primary malignancies.

Hepatotoxicity, Including Drug-Induced Liver Injury (DILI): Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of DILI, has occurred in patients treated with BTK inhibitors, including Jaypirca. Evaluate bilirubin and transaminases at baseline and throughout Jaypirca treatment. For patients who develop abnormal liver tests after Jaypirca, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold Jaypirca. If DILI is confirmed, discontinue Jaypirca.

Embryo-Fetal Toxicity: Jaypirca can cause fetal harm. Administration of pirtobrutinib to pregnant rats caused embryo-fetal toxicity, including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended 200 mg/day dose. Advise pregnant women of fetal risk and females of reproductive potential to use effective contraception during treatment and for one week after last dose.

Adverse Reactions (ARs) in Patients Who Received Jaypirca

The most common (≥30%) ARs in the pooled safety population of patients with hematologic malignancies (n=704) were decreased neutrophil count (54%), decreased hemoglobin (43%), decreased leukocytes (32%), fatigue (31%), decreased platelets (31%), decreased lymphocyte count (31%), calcium decreased (30%).

Mantle Cell Lymphoma

Serious ARs occurred in 38% of patients, with pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%) occurring in ≥2% of patients. Fatal ARs within 28 days of last dose occurred in 7% of patients, most commonly due to infections (4.7%), including COVID-19 (3.1% of all patients).

Dose Modifications and Discontinuations Due to ARs: Dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of Jaypirca in 9% of patients. Permanent discontinuation in >1% of patients included pneumonia.

Most common ARs (≥15%) and Select Laboratory Abnormalities (≥10%) (all Grades %; Grade 3-4 %): hemoglobin decreased (42; 9), platelet count decreased (39; 14), neutrophil count decreased (36; 16), lymphocyte count decreased (32; 15), creatinine increased (30; 1.6), fatigue (29; 1.6), musculoskeletal pain (27; 3.9), calcium decreased (19; 1.6), diarrhea (19; -), edema (18; 0.8), dyspnea (17; 2.3), AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included neutrophils decreased (10), platelets decreased (7), lymphocytes decreased (6).

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma from Single-Arm and Randomized Controlled Clinical Trials

Serious ARs occurred in 47-56% of patients across clinical trials. Serious ARs in ≥5% of patients in the single-arm trial were pneumonia (18%), COVID-19 (9%), sepsis (7%), febrile neutropenia (7%). Serious ARs in ≥3% of patients in the randomized controlled trial were pneumonia (21%), COVID-19 (5%), sepsis (3.4%). Fatal ARs within 28-30 days of last Jaypirca dose occurred in 8-11% of patients, most commonly due to infections (7-10%), including sepsis (5%), COVID-19 (2.7-5%), and pneumonia (3.4%).

Dose Modifications and Discontinuations Due to ARs: Dose reductions in 3.6-10%, treatment interruption in 42-51%, and permanent discontinuation of Jaypirca in 9-17% of patients. Permanent discontinuation in >1% of patients included second primary malignancy, pneumonia, COVID-19, neutropenia, sepsis, anemia, and cardiac arrhythmias.

Most common ARs and Select Laboratory Abnormalities (≥20%) (all Grades %, Grade 3-4 %)--in a randomized controlled trial: neutrophil count decreased (54; 26), hemoglobin decreased (45; 10), platelet count decreased (37; 17), pneumonia (28; 16), ALT increased (25; 1.8), creatinine increased (25; -), calcium decreased (23; 0.9), sodium decreased (22; 0.9), bilirubin increased (21; 0.9), upper respiratory tract infections (21; 0.9); in a single-arm trial: neutrophil count decreased (63; 45), hemoglobin decreased (48; 19), calcium decreased (40; 2.8), fatigue (36; 2.7), bruising (36; -), cough (33; -), musculoskeletal pain (32; 0.9), platelet count decreased (30; 15), sodium decreased (30; -), COVID-19 (28; 7), pneumonia (27; 16), diarrhea (26; -), abdominal pain (25; 2.7), lymphocyte count decreased (23; 8), ALT increased (23; 2.8), AST increased (23; 1.9), creatinine increased (23; -), dyspnea (22; 2.7), hemorrhage (22; 2.7), lipase increased (21; 7), alkaline phosphatase increased (21; -), edema (21; -), nausea (21; -), pyrexia (20; 2.7), headache (20; 0.9). Grade 4 laboratory abnormalities in >5% of patients included neutrophils decreased (23).

Drug Interactions

Strong CYP3A Inhibitors: Concomitant use increased pirtobrutinib systemic exposure, which may increase risk of Jaypirca ARs. Avoid using strong CYP3A inhibitors with Jaypirca. If concomitant use is unavoidable, reduce Jaypirca dose according to approved labeling.

Strong or Moderate CYP3A Inducers: Concomitant use decreased pirtobrutinib systemic exposure, which may reduce Jaypirca efficacy. Avoid using Jaypirca with strong or moderate CYP3A inducers. If concomitant use with moderate CYP3A inducers is unavoidable, increase Jaypirca dose according to approved labeling.

Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: Use with Jaypirca increased their plasma concentrations, which may increase risk of ARs related to these substrates for drugs sensitive to minimal concentration changes. Follow recommendations for these sensitive substrates in their approved labeling.

Use in Specific Populations

Pregnancy and Lactation: Due to potential for Jaypirca to cause fetal harm, verify pregnancy status in females of reproductive potential prior to starting Jaypirca. Presence of pirtobrutinib in human milk is unknown. Advise women to use effective contraception and to not breastfeed while taking Jaypirca and for one week after last dose.

Geriatric Use: In the pooled safety population of patients with hematologic malignancies, patients aged ≥65 years experienced higher rates of Grade ≥3 ARs and serious ARs compared to patients <65 years of age.

Renal Impairment: Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.

PT HCP ISI MCL_CLL Q42025

Please see Prescribing Information and Patient Information for Jaypirca.

About Lilly                                        
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

© Lilly USA, LLC 2026. ALL RIGHTS RESERVED. 

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ^® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Jaypirca (pirtobrutinib), as a potential treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and the timeline for future regulatory submissions, presentations, and other milestones relating to Jaypirca and its clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, or that Jaypirca will receive additional regulatory approvals. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Endnotes & References

1. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a Phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5 
2. Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1 
3. Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7 

Refer to:   Kyle Owens; Owens_Kyle@lilly.com; 332-259-3932 (Media)
                  Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-spotlight-growing-hematology-portfolio-at-2026-european-hematology-association-eha-annual-meeting-302787526.html

SOURCE Eli Lilly and Company

FAQ

What will Lilly (LLY) present at the 2026 EHA Annual Meeting?

Lilly will present multiple hematology data sets at the 2026 EHA Meeting, including Phase 3 results for Jaypirca in CLL/SLL and early-phase studies in myelofibrosis and multiple myeloma, according to Lilly.

What is the BRUIN CLL-322 Phase 3 study Lilly (LLY) is presenting at EHA 2026?

BRUIN CLL-322 is a Phase 3 trial of time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated CLL/SLL. According to Lilly, it met its primary endpoint with improved progression-free survival.

How are Ajax Therapeutics and Lilly (LLY) connected in the EHA 2026 presentations?

Ajax Therapeutics, which Lilly has agreed to acquire, will present first clinical results from the Phase 1 AJX-101 trial of type II JAK2 inhibitor AJ1-11095 in myelofibrosis patients failed by type I JAK2 inhibitors, according to Lilly.

What data will Kelonia Therapeutics share alongside Lilly (LLY) at EHA 2026?

Kelonia Therapeutics, which Lilly has agreed to acquire, will present additional correlative Phase 1 inMMyCAR data on KLN-1010, an investigational in vivo CAR-T therapy for relapsed or refractory multiple myeloma, building on results recently shown at ASCO, according to Lilly.

When and where is the 2026 EHA Annual Meeting featuring Lilly (LLY) hematology data?

The 2026 EHA Annual Meeting runs June 11-14 in Stockholm, Sweden. According to Lilly, its hematology portfolio will be featured in late-breaking oral sessions, standard oral talks, and posters across CLL/SLL, myelofibrosis and multiple myeloma.

What are the key time slots for Lilly (LLY) CLL presentations at EHA 2026?

Lilly-linked CLL data appear in several sessions, including a late-breaking oral BRUIN CLL-322 presentation on Sunday, June 14, 9:15–10:45 CEST, and multiple posters and oral sessions on June 12 and June 13, according to Lilly.